Advancing Our Understanding of IVIg in Pediatric Acute-Onset Neuropsychiatric Syndrome. Journal of Mosaic of Autoimmunity
Danieli, M.G.; Buti, E.; Longhi, E.; et al. Advancing Our Understanding of IVIg in Pediatric Acute-Onset Neuropsychiatric Syndrome. Journal of Mosaic of Autoimmunity 2025, 1 (2), 5. doi.org/10.53941/jmai.2025.100012
-
Reviews intravenous immunoglobulin (IVIg) as a pooled IgG product with broad immunomodulatory and anti-inflammatory effects.
-
Describes mechanisms including modulation of Fcγ receptors, inhibition of complement activation, cytokine regulation, and control of pro-inflammatory immune cells.
-
Explains that IVIg can influence both innate and adaptive immune systems, including via epigenetic mechanisms.
-
Summarizes evidence indicating IVIg can attenuate neuropsychiatric symptoms and restore immune balance in children with PANS.
-
Notes variability in randomized trial outcomes but highlights converging clinical and mechanistic support for IVIg in selected patients.
-
Emphasizes the need for biomarker-guided studies to identify responders and optimize treatment strategies.